UNSPSC 51283900: Sulfonamide antibacterials

This classification denotes a group of compounds that contain the structure SO2NH2. Members of this group, also known as sulfa drugs, are derivatives of sulfanilamide (an amide composed of a sulfonyl group connected to an amine, hence the names Sulfon-amide, Sulfonamide, Sulfonamides, or as here, Sulfonamide Antibacterials), which competitively inhibit folic acid synthesis in microorganisms, and are bacteriostatic. They have been largely supplanted by more effective and less toxic antibacterials.

UNSPSC 51283900 Sulfonamide antibacterials is a Class code, but the recent state and local opportunities tagged under it do not reflect sulfonamide-specific procurement. Instead, the code shows activity spanning broader pharmaceutical and medical supply categories — naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, fire-rescue medical and first aid supplies, and generic multi-source pharmaceuticals and OTC products through cooperative purchasing. The actual work being solicited reflects state health agencies, counties, and cities procuring emergency medical supplies, pharmacy benefit program support, and generic pharmaceutical inventory through competitive bidding and cooperative purchasing vehicles. The mismatch between the code's nominal scope and the recent opportunities suggests either tagging inconsistency in source systems or that this particular code receives infrequent, misaligned activity.

Geographic activity spans Florida (Seminole County naloxone procurement), Texas (HHS direct-to-manufacturer RFI), and multistate cooperative purchasing through Minnesota's MMCAP alliance serving member states including Oregon. The most recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 drug deactivation systems annually (response deadline July 26, 2023); the City of Tampa's IFB for 169 line items of medical and first aid supplies for the Fire Department Rescue Division with an estimated contract amount of $700,000 and a response deadline of March 13, 2026; the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescriptions (response deadline April 3, 2026); and Minnesota MMCAP's RFP for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026. Issuing bodies span county health departments, municipal fire departments, state health commissions, and cooperative purchasing consortia. The code shows limited recent activity, and pursuit decisions should account for the disconnect between the sulfonamide classification and the pharmaceutical and medical supply work actually being solicited.